Ondansan (Ondansetron Hydrochloride Dihydrate)

Ondansan is a 5‑HT3 antagonist used to control nausea and vomiting across several clinical pathways.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes.
• Radiotherapy‑induced nausea and vomiting: helps maintain patient comfort during and after treatment.
• Post‑operative nausea and vomiting: lowers the incidence of nausea and vomiting after surgical procedures.
• Pregnancy‑associated hyperemesis gravidarum (when other therapies are ineffective): provides symptomatic relief under specialist supervision.
• Anticipatory nausea in cancer patients: diminishes conditioned nausea responses before treatment.

• Ondansetron selectively blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents serotonin‑mediated stimulation of the vomiting centre, thereby reducing the initiation of nausea and vomiting signals.

Side effects are reported in clinical use and may vary in frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Diarrhoea: loose stools.
• Fatigue: feeling of tiredness.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• Cardiac arrhythmia (QT prolongation): may lead to irregular heartbeat.
• Severe allergic reaction (anaphylaxis): includes rash, swelling, breathing difficulty.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic enzyme elevation: abnormal liver function tests.
• Vision changes: blurred or altered vision.

When prescribing Ondansan, clinicians should consider several safety aspects.

• Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk.
• Electrolyte balance: correct hypokalaemia, hypomagnesaemia, or hypocalcaemia before use.
• Concomitant serotonergic drugs: evaluate for potential serotonin syndrome.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Renal or hepatic impairment: dose adjustment may be required based on clinical judgement.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ondansan can interact with other medicines that affect cardiac rhythm or serotonin pathways.

Major Interactions (Avoid)

• Class I anti‑arrhythmic agents (e.g., quinidine, procainamide): increase risk of QT prolongation.
• Certain macrolide antibiotics (e.g., erythromycin, clarithromycin): may elevate plasma levels of ondansetron.

Moderate Interactions (Monitor Closely)

• Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): monitor for serotonin syndrome.
• Antifungal azoles (e.g., fluconazole, ketoconazole): may raise ondansetron concentrations.
• Anticonvulsants (e.g., carbamazepine, phenytoin): may reduce ondansetron effectiveness.
• CYP3A4 inhibitors/inducers: adjust monitoring as needed.